OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETARX
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETARX
  • INVESTORS
  • NEWS
  • CONTACT

Specialty Pharmaceutical Company

PharmaTher develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting novel delivery methods to enhance patient outcomes. The Company’s lead product is KETARX™ (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is commercializing PharmaPATCH (microneedle patch) and PharmaDOSE (enteric coated) with its partners to deliver psychedelics, stem cells, gene therapy, and drugs for medical countermeasures (i.e. biothreats, infectious diseases).
Picture

Corporate Deck

OTCQB: PHRRF  |  CSE: PHRM
September 2023

Press Releases

View more press releases

Sign up for updates

SIGN UP

Connect With Us

Picture
research and development of psychedelic pharmaceuticals
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1
Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT


Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2023.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.